바이오레스토러티브 테라퓨틱스(BRTX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.73 (+2.82%), 시가총액 $0.00B, 52주 최저~최고 $0.17 ~ $2.00.
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells
바이오레스토러티브 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
바이오레스토러티브 테라퓨틱스의 현재 주가는 $2.73 (+2.82%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
바이오레스토러티브 테라퓨틱스의 시가총액은 약 $0.00B입니다.
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the tr